» Articles » PMID: 18222498

Lipid Accumulation in Non-adipose Tissue and Lipotoxicity

Overview
Journal Physiol Behav
Date 2008 Jan 29
PMID 18222498
Citations 189
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a well-known risk factor for the development of type 2 diabetes mellitus and cardiovascular disease. Importantly, obesity is not only associated with lipid accumulation in adipose tissue, but also in non-adipose tissues. The latter is also known as ectopic lipid accumulation and may be a possible link between obesity and its comorbidities such as insulin resistance, type 2 diabetes mellitus and cardiovascular disease. In skeletal muscle and liver, lipid accumulation has been associated with the development of insulin resistance, an early hallmark of developing type 2 diabetes mellitus. More specifically, accumulation of intermediates of lipid metabolism, such as diacylglycerol (DAG) and Acyl-CoA have been shown to interfere with insulin signaling in these tissues. Initially, muscular and hepatic insulin resistance can be overcome by an increased insulin production by the pancreas, resulting in hyperinsulinemia. However, during the progression towards overt type 2 diabetes, pancreatic failure occurs resulting in reduced insulin production. Interestingly, also in the pancreas lipid accumulation has been shown to precede dysfunction. Finally, accumulation of fat in the heart has been associated with cardiac dysfunction and heart failure, which may be an explanation for diabetic cardiomyopathy. Taken together, we conclude that evidence for deleterious effects of lipid accumulation in non-adipose tissue (lipotoxicity) is strong. However, while ample human data is available for skeletal muscle and the liver, future research should focus on lipid accumulation in the pancreas and the heart.

Citing Articles

Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved.

Castillo I, Argiles J, Rueda R, Ramirez M, Pedrosa J Rev Endocr Metab Disord. 2025; .

PMID: 40064750 DOI: 10.1007/s11154-025-09954-9.


Clinically Accessible Liver Fibrosis Association with CT Scan Coronary Artery Disease Beyond Other Validated Risk Predictors: The ICAP Experience.

Garcia Izquierdo B, Martinez-Urbistondo D, Guadalix S, Pastrana M, Bajo Buenestado A, Colina I J Clin Med. 2025; 14(4).

PMID: 40004749 PMC: 11856594. DOI: 10.3390/jcm14041218.


The Change of Skeletal Muscle Caused by Inflammation in Obesity as the Key Path to Fibrosis: Thoughts on Mechanisms and Intervention Strategies.

Li Y, Guo W, Li H, Wang Y, Liu X, Kong W Biomolecules. 2025; 15(1).

PMID: 39858415 PMC: 11764331. DOI: 10.3390/biom15010020.


Metabolic Chaos in Kidney Disease: Unraveling Energy Dysregulation.

Gupta P, Zhu S, Gui Y, Zhou D J Clin Med. 2024; 13(22).

PMID: 39597916 PMC: 11594442. DOI: 10.3390/jcm13226772.


Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells.

Moliterni C, Vari F, Schifano E, Tacconi S, Stanca E, Friuli M J Lipid Res. 2024; 65(12):100692.

PMID: 39505261 PMC: 11648247. DOI: 10.1016/j.jlr.2024.100692.